Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers, Small cell lung cancer
Open
Phase 3
This trial is looking at apixaban to prevent blood clots in people having treatment for lung cancer.
It is for people who are due to have treatment to the whole body. This includes chemotherapy, or for lung cancer.
You pronounce apixaban as a-pix-ah-ban.
Recruitment start: 25 March 2026
Recruitment end: 31 March 2029
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Gary Middleton
Dr Michael Newnham
University of Birmingham
Cancer Research UK Clinical Trials Unit, Birmingham
National Institute of Health Research (NIHR) Health Technology Assessment (HTA) Programme
Last reviewed: 28 Oct 2026
CRUK internal database number: 20153
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
